How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
mRNA Platform Market
- By Product Type: mRNA Therapeutics, mRNA Vaccines, mRNA Diagnostics, mRNA Research Tools, mRNA Delivery Systems
- By Application: Infectious Diseases, Oncology, Rare Genetic Disorders, Cardiovascular Diseases, Autoimmune Diseases
- By End User: Pharmaceutical and Biotechnology Companies, Research Institutes and Laboratories, Contract Research Organizations (CROs), Hospitals and Clinics, Academic and Government Research Centers
- By Delivery Technology: Lipid Nanoparticles (LNP), Polymeric Nanoparticles, Peptide-based Delivery, Electroporation, Viral Vectors
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - mRNA Therapeutics leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the mRNA Platform Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 5
Delivery Technology 5
Companies profiled
Moderna Inc.
BioNTech SE
CureVac N.V.
Translate Bio (acquired by Sanofi)
Arcturus Therapeutics Holdings Inc.
GSK (GlaxoSmithKline)
Pfizer Inc.
Sanofi S.A.
Clover Biopharmaceuticals
Imperial College London (mRNA vaccine research)
Translate Bio (Sanofi)
Gritstone Oncology
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Moderna Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →BioNTech SE
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →CureVac N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Translate Bio (acquired by Sanofi)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Arcturus Therapeutics Holdings Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →GSK (GlaxoSmithKline)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Pfizer Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Sanofi S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Clover Biopharmaceuticals
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Imperial College London (mRNA vaccine research)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Translate Bio (Sanofi)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Gritstone Oncology
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Arcturus Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →eTheRNA immunotherapies
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →CureVac
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$12,040M by 2033 · 10.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- mRNA Therapeutics59.2
- mRNA Vaccines12.0
- mRNA Diagnostics11.2
- mRNA Research Tools9.3
- mRNA Delivery Systems8.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,764M → $3,844M · 10.2%
Europe$1,230M → $2,676M · 10.2%
Asia Pacific$1,123M → $2,714M · 11.7%
Latin America$695.0M → $1,606M · 11.0%
Middle East and Africa$534.6M → $1,073M · 9.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.632026
10.642027
10.652028
10.682029
10.682030
10.692031
10.702032
10.712033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Moderna Inc.24.4
- BioNTech SE20.2
- CureVac N.V.4.5
- Translate Bio (acquired by Sanofi)11.0
- Arcturus Therapeutics Holdings Inc.7.2
- GSK (GlaxoSmithKline)4.6
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type12.0%
Application30.8%
End User29.3%
Delivery Technology28.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe22.5
- Asia Pacific22.8
- Latin America13.5
- Middle East and Africa9.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Moderna Inc. | 95 | 81 | 83 | 76 | 96 | 85 | 86 |
| BioNTech SE | 68 | 71 | 84 | 91 | 84 | 72 | 78 |
| CureVac N.V. | 74 | 88 | 74 | 81 | 68 | 71 | 76 |
| Translate Bio (acquired by Sanofi) | 81 | 78 | 57 | 65 | 76 | 60 | 70 |
| Arcturus Therapeutics Holdings Inc. | 55 | 57 | 60 | 65 | 67 | 61 | 61 |
| GSK (GlaxoSmithKline) | 71 | 56 | 65 | 59 | 48 | 59 | 60 |
| Pfizer Inc. | 58 | 60 | 42 | 66 | 44 | 50 | 53 |
| Sanofi S.A. | 40 | 53 | 42 | 45 | 40 | 58 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Moderna Inc.
- BioNTech SE
- CureVac N.V.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Moderna Inc. | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| BioNTech SE | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| CureVac N.V. | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Translate Bio (acquired by Sanofi) | ✓ | ✓ | − | − | ◐ | ◐ |
| Arcturus Therapeutics Holdings Inc. | ◐ | ◐ | − | ◐ | − | ✓ |
| GSK (GlaxoSmithKline) | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Pfizer Inc. | − | − | − | ◐ | − | ◐ |
| Sanofi S.A. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Moderna Inc.86
2BioNTech SE78
3CureVac N.V.76
4Translate Bio (acquired by Sanofi)70
5Arcturus Therapeutics Holdings Inc.61
6GSK (GlaxoSmithKline)60
7Pfizer Inc.53
8Sanofi S.A.46
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Moderna Inc.BioNTech SE
Challenger2
Strong scale, closing on the leaders.
CureVac N.V.Translate Bio (acquired by Sanofi)
Contender2
Focused players with pockets of strength.
Arcturus Therapeutics Holdings Inc.GSK (GlaxoSmithKline)
Niche2
Specialists in a single segment or region.
Pfizer Inc.Sanofi S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across mRNA Platform Market — a $119M beachhead inside a $1.98B market.
Beachhead (SOM)$119Mobtainable near-term
Serviceable (SAM)$811Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
mRNA Therapeutics
Best fit — highest urgency & budget in Product Type.
Economic buyer78 fit
mRNA Vaccines
Strong fit — clear ROI and a fast path to value.
End user66 fit
mRNA Diagnostics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win mRNA Platform Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified24%
Evaluation12%
Closed-won7%
$17.1KCAC
$98KLTV
5.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
mRNA Platform Market is a durable-growth opportunity — $4.22B by 2033, compounding at 9.3%.
TAM · 2025$2.06Btoday
TAM · 2033$4.22Bforecast
CAGR9.3%2027–2033
Cumulative$27.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.22BTotal addressable market
SAM$1.54BServiceable available market
SOM$248MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.3% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.22BLarge & growingTAM by 2033 at 9.3% CAGR
$1.54BServiceable nowreachable with today’s model
$248MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.29BBear6.1% CAGR
$4.22BBase9.3% CAGR
$5.40BBull12.3% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
mRNA Platform Market — a $6.43B market by 2033. Plan: grow share from 9.0% to 14.3%.
Market size · 2033$6.43Btotal addressable
Market CAGR5.6%2027–2033
Target share14.3%from 9.0% today
Revenue ambition$919Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 14.3% | At risk |
| Revenue | $632M | $919M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 28.4% | 45.9% | On track |
| Customer retention | 88.2% | 95.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $112M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the mRNA Platform Market conversation — a $923M market you can size, segment and defend in minutes.
Market size · 2033$923Mtotal opportunity
Growth3.7%CAGR to 2033
Addressable buyers1,217+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 2 mopayback period
$69K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Moderna Inc.BioNTech SECureVac N.V.Translate Bio (acquired by Sanofi)Arcturus Therapeutics Holdings Inc.GSK (GlaxoSmithKline)Pfizer Inc.Sanofi S.A.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your mRNA Platform Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
mRNA Platform Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →mRNA Drug Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportmRNA COVID-19 Vaccine Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportmRNA Capping Enzyme Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportMRI Tomography System Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportMRI Test Phantom Market
Market size, share, segmentation and regional forecast.
$391M market · 2025 base year
View reportMRI Suite Lighting Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportMRI Stereotaxic Instruments Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportMRI Software Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportMRI Safe Pacemaker Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportMRI Safe Cardiac Resynchronization Therapy Device Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportMRI RF Coil Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportMRI Positioning Machine Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.